Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Isaacs

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Trustee : the Journal for Hospital Governing Boards|May 1, 1997
Do the right thing. When it comes to your community, do you know what that is? Roundtable discussionJ C Bundy, M H Diamond, J C Isaacs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutationsL J Pierce, M Strawderman, S A Narod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancerS M Baidas, E P Winer, G F Fleming, et al.
Journal of the National Cancer Institute|September 2, 1999
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriersT R Rebbeck, A M Levin, A Eisen, et al.
Journal of the National Cancer Institute|July 22, 2004
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersH Jernström, J Lubinski, H T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Trustee : the Journal for Hospital Governing Boards|May 1, 1997
Do the right thing. When it comes to your community, do you know what that is? Roundtable discussionJ C Bundy, M H Diamond, J C Isaacs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutationsL J Pierce, M Strawderman, S A Narod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancerS M Baidas, E P Winer, G F Fleming, et al.
Journal of the National Cancer Institute|September 2, 1999
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriersT R Rebbeck, A M Levin, A Eisen, et al.
Journal of the National Cancer Institute|July 22, 2004
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersH Jernström, J Lubinski, H T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Pageof 7